- Novavax (NVAX, Financial) awaits new FDA guidelines to steer vaccine development.
- Analysts forecast a potential 167.10% upside in Novavax stock price.
- Current consensus recommendation marks Novavax as an "Outperform."
Novavax (NVAX) and its peers in the COVID-19 vaccine sector are on the brink of receiving pivotal regulatory updates from the FDA. This anticipated framework, expected to be released in the coming weeks, aims to streamline vaccine development processes. The announcement follows recent shifts in leadership within the Health and Human Services Department.
Wall Street Analysts Forecast
Reflecting optimism among analysts, the consensus one-year price target for Novavax Inc (NVAX, Financial) is pegged at $16.67, with projections ranging from a minimum of $9.00 to a maximum of $25.00. This average target indicates a promising potential upside of 167.10% from its current price of $6.24. Investors seeking more detailed insights can explore the Novavax Inc (NVAX) Forecast page.
Moreover, the consensus from 7 brokerage firms positions Novavax Inc (NVAX, Financial) with an average brokerage recommendation of 2.3, categorizing it under "Outperform." This rating scale ranges from 1, indicating a Strong Buy, to 5, signaling a Sell.
According to GuruFocus estimates, the projected GF Value for Novavax Inc (NVAX, Financial) over the next year is $6.12. This projection suggests a slight potential downside of 1.92% from the current trading price of $6.2399. The GF Value represents GuruFocus' assessment of the fair value at which the stock should trade, informed by historical multiples, past business growth, and future performance forecasts. For further detailed analysis, visit the Novavax Inc (NVAX) Summary page.
